Oncology Bridging the innovation gap: Scalable cell therapies, adapti... Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.
Oncology ESMO 2025 in review: A new era in oncology, from AI to next-... ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.
R&D Why gut bacteria is the next frontier in medicine Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.
News NICE backs use of MSD's KEYTRUDA for triple-negative breast ... For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy at an earlier stage of their treatment journey, as Merck & Co/MSD'
News Merck to pay BMS $625m in cancer patent case Case settles patent case related to rival immunotherapies.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.